Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masayuki Ohnaka

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of Clinical Medicine|January 8, 2025
One-Year Outcomes of Trabeculotomy with 120°, 180°, or 360° Schlemm's Canal Incision for Primary Open-Angle Glaucoma: A Retrospective StudyHidetsugu Mori, Tatsunori Kiriishi, Masatoshi Omi, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|October 16, 2016
A modified treat-and-extend regimen of aflibercept for treatment-naïve patients with neovascular age-related macular degenerationMasayuki Ohnaka, Yoshimi Nagai, Kenichiro Sho, et al.
Journal of Neurochemistry|June 26, 2012
Long-term expression of glial cell line-derived neurotrophic factor slows, but does not stop retinal degeneration in a model of retinitis pigmentosaMasayuki Ohnaka, Katsuaki Miki, Yuan-Yuan Gong, et al.
Plos One|June 10, 2026
Real-world outcomes after switching to faricimab in treatment-resistant diabetic macular edema: A 1-year observational study with choroidal thickness assessmentRyo Tomemori, Hidetsugu Mori, Mari Tanaka, et al.
Journal of Clinical Medicine|October 16, 2025
Short-Term Efficacy of Two-Step Treatment of Retinopathy of Prematurity in a Japanese Cohort: Anti-VEGF Therapy Followed by Routine Laser PhotocoagulationShimpei Oba, Tatsunori Kiriishi, Masatoshi Omi, et al.
Investigative Ophthalmology & Visual Science|September 3, 2010
Induction of arginase II mRNA by nitric oxide using an in vitro model of gyrate atrophy of choroid and retinaMasayuki Ohnaka, Emiko Okuda-Ashitaka, Shiho Kaneko, et al.
Heliyon|November 18, 2024
The effect of fibroblast growth factor 2 on neovascular vessels depends on the stage of angiogenesisYuki Hattori, Haruhiko Yamada, Hidetsugu Mori, et al.
Ophthalmology and Therapy|May 28, 2025
Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter StudyMasayuki Ohnaka, Yoichi Sakurada, Atsushi Hayashi, et al.
Biomaterials|July 16, 2013
Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptideRon B Shmueli, Masayuki Ohnaka, Akiko Miki, et al.
BMJ Open|April 21, 2026
Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trialMasahiro Miyake, Ayako Takahashi, Takayuki Baba, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Clinical Medicine|January 8, 2025
One-Year Outcomes of Trabeculotomy with 120°, 180°, or 360° Schlemm's Canal Incision for Primary Open-Angle Glaucoma: A Retrospective StudyHidetsugu Mori, Tatsunori Kiriishi, Masatoshi Omi, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|October 16, 2016
A modified treat-and-extend regimen of aflibercept for treatment-naïve patients with neovascular age-related macular degenerationMasayuki Ohnaka, Yoshimi Nagai, Kenichiro Sho, et al.
Journal of Neurochemistry|June 26, 2012
Long-term expression of glial cell line-derived neurotrophic factor slows, but does not stop retinal degeneration in a model of retinitis pigmentosaMasayuki Ohnaka, Katsuaki Miki, Yuan-Yuan Gong, et al.
Plos One|June 10, 2026
Real-world outcomes after switching to faricimab in treatment-resistant diabetic macular edema: A 1-year observational study with choroidal thickness assessmentRyo Tomemori, Hidetsugu Mori, Mari Tanaka, et al.
Journal of Clinical Medicine|October 16, 2025
Short-Term Efficacy of Two-Step Treatment of Retinopathy of Prematurity in a Japanese Cohort: Anti-VEGF Therapy Followed by Routine Laser PhotocoagulationShimpei Oba, Tatsunori Kiriishi, Masatoshi Omi, et al.
Investigative Ophthalmology & Visual Science|September 3, 2010
Induction of arginase II mRNA by nitric oxide using an in vitro model of gyrate atrophy of choroid and retinaMasayuki Ohnaka, Emiko Okuda-Ashitaka, Shiho Kaneko, et al.
Heliyon|November 18, 2024
The effect of fibroblast growth factor 2 on neovascular vessels depends on the stage of angiogenesisYuki Hattori, Haruhiko Yamada, Hidetsugu Mori, et al.
Ophthalmology and Therapy|May 28, 2025
Real-World Outcomes of Brolucizumab Treatment in Japanese Patients with Neovascular Age-Related Macular Degeneration: A 12-Month, Multicenter StudyMasayuki Ohnaka, Yoichi Sakurada, Atsushi Hayashi, et al.
Biomaterials|July 16, 2013
Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptideRon B Shmueli, Masayuki Ohnaka, Akiko Miki, et al.
BMJ Open|April 21, 2026
Reduced-fluence photodynamic therapy versus placebo for central serous chorioretinopathy (REPLAY trial): rationale and study protocol of a pivotal double-blind randomised controlled trialMasahiro Miyake, Ayako Takahashi, Takayuki Baba, et al.
Pageof 2